Assignee
ALLOGENE THERAPEUTICS INC
US·22 granted patents·29 pending applications·14 citations·filing 2015–2025
Top patents by PatentIndex Score
51 records- 0193US11673953B2DLL3 targeting chimeric antigen receptors and binding agentsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·9 cites·31 claims
- 0284US11072644B2Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2015·Granted Jul 27, 2021·2 cites·21 claims
- 0379US12221462B2Methods and compositions for dosing of allogeneic chimeric antigen receptor T cellsALLOGENE THERAPEUTICS INC·Filed 2023·Granted Feb 11, 2025·2 cites·20 claims
- 0479US12036243B2BCMA CAR-T cells with enhanced activitiesALLOGENE THERAPEUTICS INC·Filed 2021·Granted Jul 16, 2024·1 cites·32 claims
- 0578US2024360196A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0677US2024425839A1Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0776US12447178B2Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2023·Granted Oct 21, 2025·0 cites·21 claims
- 0875US2025230410A1Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0974US12104188B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 1072US2025171731A1Methods of manufacturing allogeneic car t cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1172US2025051421A1Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1271US2026042857A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1370US12583905B2Methods and compositions for dosing of allogeneic chimeric antigen receptor T cellsALLOGENE THERAPEUTICS INC·Filed 2024·Granted Mar 24, 2026·0 cites·25 claims
- 1470US2024016846A1Chimeric cytokine receptors bearing a pd-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1569US2025207199A1Methods for detecting genomic abnormalities in cellsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1668US12215347B2Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2021·Granted Feb 4, 2025·0 cites·12 claims
- 1768US11326156B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2018·Granted May 10, 2022·0 cites·17 claims
- 1867US2025333719A1Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1967US2022033462A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2066US2024101710A1B-cell maturation antigen (bcma) anti-idiotypic antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2164US12295362B2Formulations and processes for CAR T cell drug productsALLOGENE THERAPEUTICS INC·Filed 2022·Granted May 13, 2025·0 cites·20 claims
- 2264US2024003056A1Anti-talen antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2363US2024228639A1Cd70 anti-idiotype antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2462US12577290B2FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell deathALLOGENE THERAPEUTICS INC·Filed 2022·Granted Mar 17, 2026·0 cites·22 claims
- 2562US2024216430A1Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2661US12404315B2Protease-activating CD45-gate CARALLOGENE THERAPEUTICS INC·Filed 2021·Granted Sep 2, 2025·0 cites·35 claims
- 2761US12043655B2Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jul 23, 2024·0 cites·39 claims
- 2861US11896617B2Polynucleotides encoding rituximab-resistant chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Feb 13, 2024·0 cites·23 claims
- 2961US11786553B2Chimeric cytokine receptors bearing a PD-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·33 claims
- 3061US2024042030A1Engineered cells with reduced gene expression to mitigate immune cell recognitionALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3161US2023407252A1Methods for donor cell analysisALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3260US12163153B2Methods of manufacturing allogeneic CAR T cellsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Dec 10, 2024·0 cites·18 claims
- 3360US11781248B2Anti-TALEN antibodies and uses thereofALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 10, 2023·0 cites·23 claims
- 3460US2022409665A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3559US12577283B2Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell productsALLOGENE THERAPEUTICS INC·Filed 2022·Granted Mar 17, 2026·0 cites·39 claims
- 3659US2023346934A1Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signalsALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3758US2022184124A1Methods and reagents for characterizing car t cells for therapiesALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3857US12365873B2Methods for transducing immune cellsALLOGENE THERAPEUTICS INC·Filed 2022·Granted Jul 22, 2025·0 cites·29 claims
- 3957US2025380684A1Formulations and processes for car t cell drug productsALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4057US2024085403A1Method for inhibiting adventitious viral infectionALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4156US2026009000A1Methods for transducing immune cellsALLOGENE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4255US12163169B2Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·0 cites·8 claims
- 4351US11732041B2Antibodies against 4G7-derived chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Aug 22, 2023·0 cites·29 claims
- 4449US2019125799A1Methods and compositions for dosing of allogeneic chimeric antigen receptor t cellsALLOGENE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4548US12528856B2Chimeric cytokine receptors comprising TGF β binding domainsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jan 20, 2026·0 cites·40 claims
- 4648US2021106498A1Plastic Jacket for Vial Labeling SystemsALLOGENE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4748US2020399343A1Improved t cell compositions and methodsALLOGENE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4847US2023112444A1Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4944US2021062150A1Methods of preparing t cells for t cell therapyALLOGENE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5043US2020261503A1Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ALLOGENE THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →